98 /
Deprese, antidepresiva a jejich vliv na sexuální fungování
Blanco, R., Saenz de Tejada, I., Goldstein, I., Krane, R. J., Wotiz, H. H., Cohen, R. A.: Cholinergic neurotransmission in human corpus cavernosum, II: acethylcholine synthesis. Am. J. Physiol., 1988, 254: H468–H472. Bobes, J., Gonzalez, M. P., Rico-Villandemoros, F., et al.: Validotion of the Spanish version of the Changes in Sexual Functioning Questionnaire (CSFQ). J. Sex Marital Ther., 2000, 26: 119–131. Bohlen, J. G.: Sleep erection monitoring in the evaluation of male erectile failure. Urol Clin. N. Amer., 8, 1981, 1, s. 119–134. Bonierbale, M., Lancon, C., Tignol, J.: The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France. Curr. Med. Res. Opin. 2003, 19(2): 114–24. Bonnet, U.: Moclobemide: Therapeutic ese and clinical studies. CNS Drug Rev., 2003 Spring, 9(1): 97–140. Boolell, M., Allen, M. J., Ballard, S. A., Gepi-Attee, S., Muirhead, G. J., Naylor, A. M., Osterloh, I. H., Gengell, J. C.: Sildenafil: an orally active type 5 cyclic GMP–specific phosphodiesterase inhibitor for the treatment of erectile dysfunction. Int. J. Impot. Res., 1996, 8: 47–52. Bouchard, R. H., Poucher, E., Vincent, P.: Fluoxetine and extrapyramidal side effects. Am. J. Psychiatry, 1989, 146: 1352–1353. Bowers, M. B., Woert, M. V., Davis, L.: Sexual behavior during L–dopa treatment for parkinsonism. Am. J. Psychiatry, 1971, 127: 1691–1693. Boyarsky, B. K., Hirschfeld, R. M. A.: The management of medication–induced sexual dysfunction. Essent. Psychopharmacol, 2000, 3(2): 39–58. Boyarsky, B. K., Haque, W., Rouleau, M. R. et al.: Sexual functioning in depressed outpatients taking mirtazapine. Depress Anxiety, 1999, 9: 175–179. Brady, J. P., Bianco, F.: Endorhins: naloxone failure to increase sexual arousal in sexually unresponsive women: a preliminary report. Biol. Psychiatry, 1980, 15: 627–631. Brennemann, W., Stitz, B., van Ahlen, H., Brensing, K. A., Klingmuller, D.: Treatment of idiopathic erectile dysfunction in men with the opiate antagonist naltrexone: a doble–blind study. J. Androl., 1993, 14: 407–410. Bronzo, M. R., Stahl, S. M.: Galactorrhea induced by sertraline letter. Am. J. Psychiatry, 1993, 150: 1269–1270. Brown, R. P., Sweeney, J., Loutsch, E., Kocsis, J., Frances, A.: Involutional melancholia revisited. Am. J. Psychiatry, 1984, 141: 24–28. Buckley, P. F.: Sexuality and serious mental illness. Harwood academic publishers, 1999. Buckman, M. T., Kellner, R.: Reduction of disress in hyperprolactinemia with bromocriptine. Am. J. Psychiatry, 1984, 6: 351–358.
Ukázka elektronické knihy, UID: KOS180698
Literatura
/
99
Burnett, A. L.: Role of nitric oxide in the physiology of erection. Biol. Reprod., 1995, 52: 485–489, Burnett, A. L.: Nitric oxide in the penis: physiology and pathology. J. Urol., 1997, 157: 320–324. Burnett, A. L., Calvin, D. C., Silver, R. I., Peppas, D. S., Domico, S. G.: Immunohistochemical description of nitric oxide synthase isiforms in human clitoris. J. Urol., 1997, 158: 75–78. Burnett, A. L., Lowenstein, C. J., Bredt, D. S. et al.: Nitric oxide: a physiologic mediator of penile erection. Science, 1992, 257: 401–403. Buvat, J. et al.: Is intracavernous injection of Papaverine a reliable screening test for vascular impotence. J. Urol., 135, 1986, 3, s. 476–478. Cara, A. M., Lopes-Martins, R. A. B., Antunes, E., Nahoum, C. R,.D., Nucci, D. E.: The role of histamine in human penile erection. Br. J. Urol., 1995, 75: 220–224. Carini, C., Bancroft, J., Del Rio, G., Granata, A. R. M., Facchiinetti F., Marrama, P.: The endocrine effects of visual erotic stimuli in normal men. Psychoneuroendocrinology. 1990, 15: 207–216. Carmichael, M. S., Humbert, R., Dixen, J., Palmisano, G., Greenleaf, W., Davidson, J. M.: Plasma oxytocin increases in the human sexual response. J. Endocrinol. Metab.. 1987, 64: 27–31. Carmichael, M. S., Warburton, V. L., Dixen, J., Davidson, J. M.: Relationships among cardiovascular, muscular, and oxytocin responses during human sexual activity. Arch. Sex Behav., 1994, 23: 59–77. Carter, C. S.: Oxytocin and sexual behavior. Neurosci. Biobehav. Rev., 1992, 16: 131–144. Casper, R. C., Katz, M. M., Bowden, C. L., Davis, J. M., Koslow, S. H., Hanin, I.: The pattern of physical symptom changes in major depressive disorder following treatment with amitriptyline or imipramine. J. Affect. Disord., 1994, 31: 151–164. Casper, R. C., Redmond, F., Kutz, M. M. et al.: Somatic symptoms in primary affectiuve disorders: presence and relationship to the classification of depression. Arch. Gen. Psychiatry, 1985, 42: 1098–1104. Cassidy, W. L., Flanagan, N. B., Spellman, M., Cohen, M. E.: Clinical observations in manic depressive disease: a quantitative study of 100 manic depressive patients and 50 medically sick controls. JAMA, 1957, 154: 1535–1546. Clark, J. T., Stefanick, M. L., Smith, E. R., Davidson, J. M.: Further studies on alterations in male rat copulatory behavior induced by the dopamine–receptor agonists RDS–127. Pharmacol. Biochem. Behav., 1983, 19: 781–786.
Ukázka elektronické knihy, UID: KOS180698
100 /
Deprese, antidepresiva a jejich vliv na sexuální fungování
Clayton, A. H., McGarvey, E. L., Abouesh, A. L., Pinkerton, R. C.: Substitution af an SSRI with bupropion sustained release following SSRI–induced sexual dysfunction. J. Clin. Psychiatry, 2002(a) 62: 185–190. Clayton, A. H., McGarvey, E. L., Clavet, G. J.: The Changes in Sexual Functioning Questionnaire ( CSFQ ): developement, reliability, and validity. Psychopharmacol Bull., 1997 (a), 33: 731–745. Clayton, A. H., Mc Garvey, E. L., Clavet, G. J., Piazza, L.: Comparison of sexual functioning in clinical and non–clinical populations using the Changes in Sexual Functioning Questionnare (CSFQ). Psychopharmacol Bull, 1997 (b), 33: 747–753. Clayton, A. H., Clavet, G. J., McGarvey, E. L. et al.: Assessment of sexual functioning during the menstrual cycle. J. Sex Marital Ther., 1999, 25: 281–291. Clayton, A. H., Pradko, J. F., Croft, H. A., Montano, C. B., Leadbetter, R. A., Bolden-Watson, C. et al.: Prevalence of sexual dysfunction among newer antidepressants. J. Clin. Psychiatry, 2002(b), 63: 357–366. Clayton, A. H., Owens, J. E., McGarvey, E. L.: Assessment of paroxetine-induced sexual dysfunction using the Changes in Sexual Functioning Questionnaire. Psychopharmacol Bull., 1995, 31: 397–413. Clayton, A. H., Zajecka, J., Ferguson, J. M.: Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. Int. Clin. Psychopharmacology, 2003, 18: 151–156. Clopper, R. R., Voorhess, M. L., MacGillivray, M. H., Lee, P. A., Mills, B.: Psychosexual behavior in hypopituitary men: a controlled comparison of gonadotropin and testosterone replacement. Psychoneuroendocrinology, 1993, 18: 149–161. Cohen, S.: Cocaine. JAMA, 1975, 231: 74–75. Cohen, M. A., Davies, P. H.: Drug therapy and hyperprolactinemia. Adverse Drug React Bull., 1998, 190: 723–726. Cohen, A. S., Rosen, R. C., Goldstein, L.: EEG hemispheric asymmetry during sexual arousal: Psychophysiological patterns in responsive, unresponsive, and dysfunctional men. J. Abnorm. Psychol., 1985, 94: 580–590. Cohn, B. A.: In search of human skin pheromones [a review]. Aarch Dermatol., 1994, 130: 1048–1051. Coleman, C. C., Cunningham, L. A., Foster, V. J. et al.: Sexual dysfunction associated with the treatment of depression: a placebo–controlled comparison of bupropion sustained release and sertraline treatment. Ann. Clin. Psychiatry, 1999, 11: 205–215. Coppen, A.: The prevalence of menstrual disorders in psychiatric patients. Br. J. Psychiatry, 1965, 111: 155–167.
Ukázka elektronické knihy, UID: KOS180698